Glucose alerts tested in hospital diabetes study
NCT ID NCT05941286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether alerts from continuous glucose monitors (CGMs) help hospital patients with type 1 or 2 diabetes manage their blood sugar better. Over 500 adults who needed intensive insulin therapy took part. The main goal was to see if alerts increased the time blood sugar stayed in a healthy range.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
533 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males and females ≥ 18 years. 2. Type 1 or type 2 diabetes with suboptimal glucose control requiring hospitalization, as determined by endocrinologists following clinical guidelines. 3. Willingness and ability to comply with the clinical investigation plan. Exclusion Criteria: 1. significant hyperglycemia or diabetic ketoacidosis requiring continuous intravenous insulin infusion. 2. Female subjects who are pregnant or have a plan of pregnancy at time of enrollment into the study. 3. Current users of real-time glucose monitoring sensors or flash-glucose monitoring. 4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area. 5. Patients expected to require operation, admission to the ICU and MRI procedures during hospitalization. 6. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- Can diverse tissue samples unlock Obesity's secrets?
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Personalized nursing care may boost diabetes Self-Management